Central Nervous System Ischemia Associated with Bevacizumab: An Analysis of the Japanese Adverse Drug Event Report Database
-
- Sugimoto Shohei
- Graduate School of Integrated Arts and Sciences, Kochi University Yell Pharmacy Corporation
-
- Ishida Tomoaki
- Department of Pharmacy, Kochi Medical School Hospital
-
- Kawada Kei
- Graduate School of Integrated Arts and Sciences, Kochi University Department of Pharmacy, Kochi Medical School Hospital
-
- Jobu Kohei
- Department of Pharmacy, Kochi Medical School Hospital
-
- Morisawa Shumpei
- Department of Pharmacy, Kochi Medical School Hospital
-
- Tamura Naohisa
- Graduate School of Integrated Arts and Sciences, Kochi University Department of Pharmacy, Kochi Medical School Hospital
-
- Takuma Daisuke
- Yell Pharmacy Corporation
-
- Yoshioka Saburo
- Graduate School of Integrated Arts and Sciences, Kochi University
-
- Miyamura Mitsuhiko
- Graduate School of Integrated Arts and Sciences, Kochi University Department of Pharmacy, Kochi Medical School Hospital
この論文をさがす
説明
<p>Bevacizumab is an inhibitor of vascular endothelial growth factor (VEGF) that prevents tumor growth. While bevacizumab is therapeutically effective, it induces several adverse events. Among these, central nervous system (CNS) ischemia can lead to death or permanent disability. In this study, we reviewed the Japanese Adverse Drug Event Report database to analyze the occurrence of CNS ischemia after bevacizumab administration. Significant associations between the occurrence of CNS ischemia and bevacizumab use were detected (adjusted reporting odds ratios (ROR): 2.68, 95% confidence interval (CI): 2.00–3.59, p < 0.001). Furthermore, an association between diagnosis of glioma and bevacizumab use was also detected (p < 0.001). These events occurred early after the start of treatment and then gradually decreased; however, more than half of CNS ischemia events were reported beyond 30 d after the first administration. In addition, a logistic regression suggested that CNS ischemia caused by bevacizumab was associated with glioma, underlying hypertension and aging. A poor prognosis was reported for several cases occurring in elderly patients (over 60 years of age). Although bevacizumab is a useful pharmacological treatment for cancer, caution should be taken to avoid severe adverse events. Accordingly, the patient’s general and medical condition should be carefully examined before initiating treatment, and blood pressure should be continuously assessed throughout treatment with bevacizumab to prevent CNS ischemia.</p>
収録刊行物
-
- Ｂｉｏｌｏｇｉｃａｌ ＆ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｂｕｌｌｅｔｉｎ
-
Ｂｉｏｌｏｇｉｃａｌ ＆ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｂｕｌｌｅｔｉｎ 45 (12), 1805-1811, 2022-12-01
公益社団法人 日本薬学会